02 Aug 2023 CDR-Life Announces Second Milestone Achievement with Boehringer Ingelheim in Developing Antibody Fragment-based Therapeutics for Geographic Atrophy
02 Aug 2023 Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
01 Aug 2023 China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab
01 Aug 2023 Doer Biologics Announces First Subject Dosed in Phase I 12-Week Multiple-Ascending Dose (MAD) Clinical Trial of DR10624 and Received IND Approval From NMPA
01 Aug 2023 Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar
01 Aug 2023 Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma
01 Aug 2023 Jemperli (dostarlimab) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer
31 Jul 2023 NMPA and FDA Approved the First-in-Human Clinical Trial Applications to Evaluate LBL-034, An Anti-GPRC5D/CD3 Bispecific Antibody Developed by Leads Biolabs, in Relapsed/Refractory Multiple Myeloma
31 Jul 2023 Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density
28 Jul 2023 Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
28 Jul 2023 Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
28 Jul 2023 Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
28 Jul 2023 European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer -- Approval Based on Clinically Meaningful Overall Survival Benefit Demonstrated in the
28 Jul 2023 Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization
27 Jul 2023 Cessation Therapeutics Announces Food and Drug Administration Authorization for First-in-Human Clinical Trial of Antibody for Prevention of Fentanyl Overdose
27 Jul 2023 SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study
27 Jul 2023 Soliris approved in the EU for children and adolescents with refractory generalised myasthenia gravis (gMG)
27 Jul 2023 Enhertu demonstrated clinically meaningful progression-free survival and overall survival across multiple HER2-expressing advanced solid tumours in DESTINY-PanTumor02 Phase II trial
25 Jul 2023 Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
25 Jul 2023 ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates
25 Jul 2023 Epsilogen Announces Successful Completion of First Ever Clinical Trial of an IgE Antibody; Phase I Data for MOv18 IgE Demonstrates Potential of IgE Therapy in Cancer
25 Jul 2023 Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program
25 Jul 2023 Biocon Biologics Announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept
25 Jul 2023 STADA and Xbrane weigh options for ranibizumab biosimilar candidate
24 Jul 2023 Fresenius Kabi’s tocilizumab biosimilar receives positive opinion on Marketing Authorization Application (MAA) for Europe

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up